Stock Market

Is Moderna Stock a Buy After it was Announced it Will Join the S&P 500? By StockNews

© Reuters. Is Moderna Stock a Buy After it was Announced it Will Join the S&P 500?

Moderna (NASDAQ:) gained immense popularity over the past year owing to its highly effective COVID-19 vaccine, as evidenced by its shares’ triple-digit gains over this period. The stock was included in the benchmark S&P 500 index today before the markets opened. However, with a large proportion of the global population being vaccinated daily, and many other vaccine producers gaining market share, will MRNA’s COVID-19 vaccine business continue to grow? Read more to find out.Biotech company Moderna, Inc. (MRNA), which is based in Cambridge, Mass., and is now known for its COVID-19 vaccine, was included in the S&P 500 index today, before markets opened. Shares of MRNA have surged 22.8% since the the July 15 news of its S&P 500 inclusion to close yesterday’s trading session at $307.33. More than $34 billion of MRNA shares were traded yesterday, 1,600% higher than its average trading volume, worth $2 billion, recorded over the past six months.

MRNA’s growth trajectory over the past year has been impressive. Founded a mere 11 years ago, MRNA’s COVID-19 vaccine candidate put the company on the map, leading to its inclusion in one of the most significant benchmark indexes. MRNA has gained 271.7% over the past year and 194.2% year-to-date.

The company is currently developing a single-shot booster vaccine amid rising global concerns related to the COVID-19 Delta variant. The company announced positive results from its phase 2 study on May 25. MRNA CEO Stéphane Bancel said, “We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants.” Shares of MRNA have gained 87.2% since the release of this data on May 25.

Continue reading on StockNews

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Related Articles

Back to top button